Halozyme Therapeutics' (HALO) "Buy" Rating Reaffirmed at HC Wainwright

Halozyme Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright reaffirmed its Buy rating on Halozyme Therapeutics and set a $130 price target, implying 39.72% upside from the prior close.
  • Analyst views are mixed overall: MarketBeat reports an average Hold rating and a $108.18 average price target, with seven Buy, five Hold, and one Sell rating.
  • Halozyme beat quarterly earnings and revenue estimates, with revenue up 39.1% year over year. Separately, a German court overturned a preliminary injunction against Merck’s Keytruda SC, leaving Halozyme’s patent dispute unresolved.
  • Interested in Halozyme Therapeutics? Here are five stocks we like better.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a report issued on Friday, Benzinga reports. They presently have a $130.00 price objective on the biopharmaceutical company's stock. HC Wainwright's target price points to a potential upside of 39.72% from the stock's previous close.

A number of other brokerages also recently commented on HALO. Wall Street Zen downgraded Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Saturday, November 7th. Citigroup reissued a "market outperform" rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Citizens Jmp upped their target price on shares of Halozyme Therapeutics from $93.00 to $149.00 and gave the company a "market outperform" rating in a research note on Friday, November 6th. Stifel Nicolaus set a $130.00 target price on Halozyme Therapeutics in a research report on Friday, October 16th. Finally, Leerink Partners cut shares of Halozyme Therapeutics from an "outperform" rating to a "hold" rating and increased their price target for the stock from $110.00 to $117.00 in a research report on Friday, November 6th. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $108.18.

View Our Latest Analysis on HALO

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $93.04 on Friday. The company has a debt-to-equity ratio of 13.50, a quick ratio of 3.60 and a current ratio of 3.88. The company has a market capitalization of $10.61 billion, a price-to-earnings ratio of 23.67, a PEG ratio of 0.36 and a beta of 0.92. The company's 50 day simple moving average is $113.53 and its 200 day simple moving average is $85.96. Halozyme Therapeutics has a 1 year low of $61.22 and a 1 year high of $134.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 EPS for the quarter, topping the consensus estimate of $2.30 by $0.09. The firm had revenue of $492.97 million during the quarter, compared to analysts' expectations of $491.63 million. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. Halozyme Therapeutics's revenue for the quarter was up 39.1% on a year-over-year basis. During the same period in the previous year, the company earned $1.72 EPS. On average, sell-side analysts predict that Halozyme Therapeutics will post 8.34 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Monday, November 16th. The stock was sold at an average price of $98.38, for a total transaction of $1,967,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $75,534,196.40. This trade represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 18th. The stock was sold at an average price of $96.43, for a total value of $482,150.00. Following the completion of the transaction, the director owned 48,609 shares in the company, valued at $4,687,365.87. This represents a 9.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 149,226 shares of company stock valued at $15,744,643 in the last 90 days. Corporate insiders own 2.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Thoroughbred Financial Services LLC lifted its holdings in shares of Halozyme Therapeutics by 0.4% during the third quarter. Thoroughbred Financial Services LLC now owns 22,336 shares of the biopharmaceutical company's stock worth $2,465,000 after buying an additional 100 shares during the last quarter. Mather Group LLC. grew its stake in shares of Halozyme Therapeutics by 48.9% in the 3rd quarter. Mather Group LLC. now owns 414 shares of the biopharmaceutical company's stock valued at $46,000 after purchasing an additional 136 shares during the period. North Dakota State Investment Board raised its stake in Halozyme Therapeutics by 4.3% during the third quarter. North Dakota State Investment Board now owns 3,598 shares of the biopharmaceutical company's stock worth $397,000 after acquiring an additional 147 shares in the last quarter. CoreCap Advisors LLC lifted its holdings in Halozyme Therapeutics by 98.0% during the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 150 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 3.5% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 4,515 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 151 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Key Headlines Impacting Halozyme Therapeutics

These are some of the HALO headlines that stood out recently:

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Featured Stories

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Halozyme Therapeutics Right Now?

Before you consider Halozyme Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.

While Halozyme Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines